London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; United BioSource Corporation, 20 Bloomsbury Square, London WC1A 2NS, UK.
Expert Rev Pharmacoecon Outcomes Res. 2008 Oct;8(5):453-61. doi: 10.1586/14737167.8.5.453.
Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using condition-specific data to generate QALYs. There are two main methods: mapping from the condition-specific data to a generic health-related quality of life measure; and direct valuation of condition-specific health states. Whether one believes condition-specific data are useful even if generic QALY data are available, or simply that condition-specific data are helpful in the absence of generic measures of health-related quality of life, it is timely to review recent research activity directed at making greater use of condition-specific data to inform assessments of cost-effectiveness.
质量调整生命年(QALYs)在报销决策中起着重要作用,当其中一个标准是卫生技术的成本效益时。虽然对于许多通用 QALYs(例如,基于 EQ-5D)被视为黄金标准,但使用特定于病情的数据来生成 QALYs 的兴趣显著增加。有两种主要方法:从特定于病情的数据映射到通用的健康相关生活质量衡量标准;以及直接对特定于病情的健康状况进行估值。无论是否认为即使有通用 QALY 数据,特定于病情的数据也有用,或者仅仅认为在缺乏健康相关生活质量的通用衡量标准的情况下,特定于病情的数据有帮助,现在及时审查最近的研究活动,以便更广泛地使用特定于病情的数据来为成本效益评估提供信息是很有必要的。